Cytomegalovirus vaccine live - Xenova

Drug Profile

Cytomegalovirus vaccine live - Xenova

Latest Information Update: 30 May 2002

Price : $50

At a glance

  • Originator Xenova Group
  • Class Cytomegalovirus vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 26 May 2002 Discontinued - Preclinical for Cytomegalovirus infections in United Kingdom (unspecified route)
  • 26 Jun 2001 No-Development-Reported for Cytomegalovirus infections in United Kingdom (Unknown route)
  • 30 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top